What MID-35 is
MID-35, also indexed as Myostatin-IN-1, is a synthetic 16-amino-acid retro-inverso D-peptide with a molecular weight of approximately 2,350.9 Da. Reversing the parent sequence while using D-amino acids is intended to preserve the relevant side-chain arrangement while making the peptide difficult for ordinary proteases to degrade. In isolated trypsin and chymotrypsin solutions, 99% and 97% of MID-35 remained intact after 400 minutes.
The mechanism fits a local-growth hypothesis
Myostatin is a negative regulator of skeletal-muscle growth. Its signaling through activin receptors and Smad2/3 restrains protein synthesis, promotes atrophy programs, and limits satellite-cell activation and differentiation. MID-35 is designed to bind the active ligand and reduce that inhibitory signal. This is different from adding androgen-receptor stimulation: the thesis is to reduce a muscle-growth brake inside the treated tissue.
It is preferential, not myostatin-exclusive
In the founding reporter assay, the half-maximal inhibitory concentrations were 0.19 µM for myostatin, 0.63 µM for GDF-11, 0.89 µM for activin A, and 1.6 µM for TGF-β1. A separate cell assay did not reproduce the activin A effect under its conditions. The selectivity profile is therefore assay-dependent and unresolved. The defensible description is a myostatin-preferring inhibitor with activity against related TGF-β-family signaling, not a perfectly selective switch.
The first local mouse result was large
In 2022, researchers injected 30 nmol into the left tibialis anterior muscle of five healthy eight-week-old male mice and saline into the right muscle. After 28 days, the treated muscle weighed 133 ± 10% as much as its saline control. The experiment established a substantial local mouse-muscle signal, but it did not measure whole-body lean mass, force production, exercise performance, pharmacokinetics, or systemic safety.
It also reduced wasting in cachectic mice
A second 2022 study used Lewis-lung-carcinoma cachexia mice. Six mice per group received 30 nmol per leg on days 4, 11, and 18. MID-35 reduced the loss of gastrocnemius fiber area and improved grip strength compared with vehicle, but did not improve survival on its own. Combining it with anamorelin produced the highest grip strength and a borderline survival result at p=0.052. That is useful anti-wasting evidence in a severe disease model, not proof of added hypertrophy in a healthy trained person.
The iontophoresis result was not internally clean
In 2023, five mice per group received 75 nmol through electrically assisted skin delivery on days 0, 7, and 14. Tibialis anterior weight was approximately 25% higher on day 42, while gastrocnemius weight did not increase significantly. Average muscle-fiber cross-sectional area was unchanged, and most shifts in the fiber distribution were nonsignificant. The study supports local delivery and a muscle-weight effect, but does not fully establish what made the tissue heavier.
The 2026 study found a durable remodeling response
The newest study injected 2 nmol into one tibialis anterior and saline into the opposite side of young, adult, and aged male mice. In young mice, satellite-cell and differentiation markers rose and atrophy markers fell within three days. Muscle weight first increased significantly on day 14 and remained higher on day 84 after the one administration. Histology showed a shift toward larger fibers, increased Pax7-positive signals, and extensive centralized nuclei, supporting a regeneration-and-remodeling response. The study did not measure strength, fatigability, trained-muscle adaptation, systemic exposure, or toxicology.
S1P is an associated mechanism, not a proven driver
Sphingosine-1-phosphate increased on day 3 in young and adult muscle but not significantly in aged muscle. That change coincided with early satellite-cell activation and may help explain the remodeling response. The researchers did not manipulate S1P independently, so the study cannot establish that S1P caused the hypertrophy. None of the measured pathways explained why the structural effect remained on day 84.
Twelve weeks of effect is not a measured 12-week half-life
The 2026 investigators inferred that the direct pharmacodynamic action was probably concentrated inside the first seven days because the early gene signals normalized. The muscle created during that window then remained larger. No study has measured MID-35's local or systemic half-life, biodistribution, clearance, or accumulation in an animal or person.
Human translation remains unknown
The active myostatin sequence is conserved between mice and humans, making target binding plausible across species. That does not establish human effect size, tissue penetration, dose, or safety. Other human myostatin-pathway drugs have sometimes increased lean mass without consistently improving function. I found no published human administration of MID-35 and no registered ClinicalTrials.gov study.
Supporting tissue is part of the uncertainty
Myostatin also participates in tendon and extracellular-matrix biology. Complete myostatin deficiency in animals has produced smaller, stiffer, less cellular tendons and altered collagen-related phenotypes. Those knockout models do not predict what a local MID-35 exposure would do, but they make tendon symptoms, range of motion, and the relationship between added muscle force and supporting-tissue adaptation relevant outcomes rather than generic warnings.
Evidence quality
The biological evidence consists of small mouse experiments, generally five or six animals per group, produced by overlapping Japanese academic teams. The healthy-animal experiments used growing male mice and targeted a single muscle; none used resistance-trained animals. There is no independent replication, formal human dose conversion, systemic exposure study, repeat-dose toxicology, immunogenicity program, or established reversal strategy.